(600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 600572 · · 18 pages · Chinese
Zhejiang CONBA Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang CONBA Pharmaceutical
- (600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on the Listing and Trading of Restricted Shares under the Split Share Structure Reform
- (600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Indicative Announcement on the Restricted Exercise Period under the 2022 Stock Option Incentive Plan
- (600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on the Shareholding Reduction Plan of Shareholder through Call Auction
- (600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Self-exercise Results in Q3 2026 under the Stock Option Incentive Plan and Share Changes
- (600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Receipt of Drug Registration Certificate for Dapoxetine Hydrochloride Tablets by Subsidiary
Later from Zhejiang CONBA Pharmaceutical
- (600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Cancellation of Certain Stock Options under the 2022 Stock Option Incentive Plan
- (600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Satisfaction of Exercise Conditions for the Second Exercise Period of Stock Options of the Reserved Grant under the 2022 Stock Option Incentive Plan
- (600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Satisfaction of Exercise Conditions for the Third Exercise Period of Stock Options of the Initial Grant under the 2022 Stock Option Incentive Plan
Follow Zhejiang CONBA Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang CONBA Pharmaceutical